Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics announced that it has executed a definitive contract manufacturing agreement worth approximately KRW 1.464T with a pharmaceutical company based in the U.S.
📊 [Key Disclosure Details & Summary Statistics]
- Contract Classification: Sales/Supply Contract (Contract Manufacturing Agreement for Pharmaceutical Products)
- Contract Amount: KRW 1,463,679,344,160 (KRW ~1.464T) / USD 1,060,022,700
- Recent Annual Revenue: KRW 3,694,588,767,068 (Based on 2023 consolidated financial statements)
- Contract Ratio to Revenue: 39.62%
- Large Corporation Status: Applicable
- Counterparty: Pharmaceutical company located in the U.S.
- Contract Period: June 27, 2024 – December 31, 2030
- Contract (Order) Date: July 2, 2024
- Non-disclosure of Counterparty Details:
- Postponement Period for Counterparty Disclosure: Until December 31, 2030 (Due to business trade secrecy)
- Other Key Investment Matters:
- The contract amount was converted using the initial FX rate of USD/KRW 1,380.80 on July 2, 2024, based on the confirmed amount of USD 1,060,022,700.
- This contract represents the execution of the definitive main contract following the previous LOI disclosure (‘Major Management Matters’) filed on June 5, 2023.
- The contract end date is subject to change based on mutual agreement between both parties.
- The scheduled counterparty disclosure date is subject to change in the future.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Main Contract Terms and Order Backlog Status in Periodic Reports
This disclosure marks the transition of a previously signed letter of intent (LOI) into a definitive main contract valued at approximately KRW 1.464T. Reviewing any changes in contract terms or amounts compared to the initial LOI, as well as potential future adjustments to the contract amount or period, is important for understanding how this large-scale order translates into realized revenue. Relevant updates and order details can be verified in subsequent disclosures or periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided strictly for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
